vTv Therapeutics (NASDAQ:VTVT) Releases Earnings Results, Beats Estimates By $0.15 EPS

vTv Therapeutics (NASDAQ:VTVT) issued its earnings results on Thursday. The biotechnology company reported ($0.94) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.15, FiscalAI reports.

vTv Therapeutics Price Performance

Shares of NASDAQ VTVT traded down $0.71 during trading on Friday, hitting $21.03. The stock had a trading volume of 14,366 shares, compared to its average volume of 21,551. vTv Therapeutics has a 12 month low of $20.56 and a 12 month high of $44.00. The company has a market capitalization of $82.86 million, a PE ratio of -22.86 and a beta of 0.28. The firm has a fifty day moving average of $29.22 and a two-hundred day moving average of $33.23.

Analyst Upgrades and Downgrades

A number of analysts have commented on VTVT shares. Weiss Ratings lowered shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Zacks Research raised shares of vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, September 7th. Wall Street Zen upgraded shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. BTIG Research reaffirmed a “buy” rating and issued a $57.00 price target on shares of vTv Therapeutics in a research report on Wednesday, October 14th. Finally, Lifesci Capital upgraded vTv Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $55.83.

vTv Therapeutics Company Profile

vTv Therapeutics Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer’s disease.